malvernmugadzikwa
Sunday Mail Correspondent
INTERNATIONAL recognition through Maturity Level 3 can boost pharmaceutical trade by building trust among global manufacturers and investors.
The Medicines Control Authority of Zimbabwe (MCAZ)’s attainment of the World Health Organisation (WHO) global benchmarking tool — Maturity Level 3 (ML3) — is significant for several reasons, as highlighted below:
Enhanced public health safety
Achieving ML3 signifies that the MCAZ has a stable, well-functioning and integrated regulatory system.
This ensures that all medicines and vaccines available in Zimbabwe meet high standards of quality, safety and efficacy.
As a result, Zimbabweans can have increased confidence in the safety of medical products, which is crucial for public health.
International recognition
ML3 status places the MCAZ among the ranks of globally recognised regulatory authorities.
This can enhance Zimbabwe’s reputation on an international level, fostering trust and credibility with global health organisations, donors and other countries’ regulatory bodies.
Improved access to medicines and vaccines
With a robust regulatory system, Zimbabwe is better positioned to facilitate quicker and more reliable access to essential medicines and vaccines.
This is particularly important during health emergencies, as it ensures that life-saving products can be efficiently approved and distributed.
Economic and trade benefits
International recognition through ML3 can boost pharmaceutical trade by building trust among global manufacturers and investors.
It can also encourage local production by ensuring that products manufactured in Zimbabwe meet international standards, thereby opening up export opportunities.
Capacity for continuous improvement
ML3 indicates that the regulatory system is not only effective, but is also capable of continuous improvement.
This means the MCAZ can adapt to new challenges and advancements in medicine and technology, maintaining its ability to protect public health effectively.
Support for universal health coverage
Attaining ML3 aligns with global health goals, such as those outlined in the Sustainable Development Goal 3, which strives for universal health coverage and access to safe, effective, quality and affordable essential medicines and vaccines for all.
Strengthened regulatory practices
Achieving this milestone typically involves comprehensive reviews and enhancements of regulatory policies, procedures and practices.
This strengthens various aspects of the regulatory framework, including pharmacovigilance, market surveillance and regulatory inspections, contributing to an overall improvement in the national healthcare system.
Conclusion
The attainment of ML3 by the MCAZ is a major milestone that highlights its commitment to regulatory excellence and public health.
It reflects Zimbabwe’s ability to meet international standards
and provides a framework for continuous improvement, ultimately benefitting the health and well-being of its people.
Online Reporter